Drug Trial Radar · NCT05483907
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
Last checked: Nov 19, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Apr 12, 2023
Primary completion
Jan 26, 2025
Study completion Feb 23, 2025
Sponsor
- Lead sponsor
- Bridge Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
BBT-877Drug
BBT-877 24 weeks + Follow-up 4 weeks
PlaceboDrug
Placebo 24 weeks + Follow-up 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- In patients with IPF by measuring the reduction in forced vital capacity (FVC) in mL decline compared to placeboTime frame: After 24 weeks of treatment
Locations
44 sites in 5 countries. Site status is shown where the registry gives one.
Pulmonary Associates P.A.
Phoenix, Arizona
Southern Arizona VA Health Care System - NAVREF - PPDS
Tucson, Arizona
Keck Medical Center of USC
Los Angeles, California
VA Palo Alto Health Care System
Palo Alto, California
National Jewish Health Main Campus
Denver, Colorado
St. Francis Medical Institute - Clinedge
Clearwater, Florida
Renstar Medical Research
Ocala, Florida
Central Florida Pulmonary Group PA
Orlando, Florida
Augusta University
Augusta, Georgia
Northwestern Memorial Hospital
Chicago, Illinois
Loyola University Medical Center
Maywood, Illinois
The Lung Research Center, LLC
Chesterfield, Missouri
Hannibal Regional Healthcare System-HRMG-Hannibal
Hannibal, Missouri
Medical University of South Carolina
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Premier Pulmonary Critical Care & Sleep Medicine
Denison, Texas
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Royal Brisbane & Women's Hospital
Herston, Queensland, Australia
Institute for Respiratory Health
Nedlands, Western Australia, Australia
Barzilai Medical Center
Petah Tikva, Israel
Rabin Medical Center
Petah Tikva, Israel
Kaplan Medical Center
Rehovot, Israel
Meir Medical Center
Kfar Saba, Central District, Israel
Lady Davis Carmel Medical Center
Haifa, Haifa District, Israel
Hadassah Medical Center
Jerusalem, Jerusalem, Israel
Tel Aviv Sourasky Medical Center
Ashkelon, Southern District, Israel
Sheba Medical Center
Ramat Gan, Tel Aviv, Israel
Vitamed Galaj i Cichomski sp.j.
Bydgoszcz, Poland
Centrum Dentystyczno Lekarskie Promedica Joanna Markiewicz
Będzin, Silesian Voivodeship, Poland
Inje University Haeundae Paik Hospital
Busan, South Korea
Kyung Hee University Hospital
Seoul, South Korea
Severance Hospital Yonsei University
Seoul, South Korea
Soon Chun Hyang University Hospital Seoul
Cheonan, Chungcheongnam-do, South Korea
Samsung Medical Center
Seoul, Gangnam-gu, South Korea
The Catholic University of Korea, Bucheon St. Mary's Hospital
Bucheon-si, Gyeonggi-do, South Korea
CHA Bundang Medical Center, CHA University
Seongnam-si, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Myongji Hospital
Goyang-si, Gyeonggido, South Korea
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.